This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Shoulder Innovations, Inc. (SI), Maze Therapeutics, Inc. (MAZE) and PACS Group Inc (PACS)

Tipranks - Tipranks - Fri May 15, 7:56AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Shoulder Innovations, Inc. (SI), Maze Therapeutics, Inc. (MAZE) and PACS Group Inc (PACS) with bullish sentiments.

Claim 55% Off TipRanks

Shoulder Innovations, Inc. (SI)

In a report released yesterday, David Roman from Goldman Sachs maintained a Buy rating on Shoulder Innovations, Inc., with a price target of $20.00. The company’s shares closed last Wednesday at $13.53.

According to TipRanks.com, Roman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.7% and a 34.3% success rate. Roman covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., GE Healthcare Technologies Inc, and Bausch + Lomb Corporation. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Shoulder Innovations, Inc. with a $21.50 average price target, implying a 62.1% upside from current levels. In a report issued on May 8, Piper Sandler also maintained a Buy rating on the stock with a $19.00 price target.

See today’s best-performing stocks on TipRanks >>

Maze Therapeutics, Inc. (MAZE)

In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Maze Therapeutics, Inc.. The company’s shares closed last Wednesday at $26.96.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 13.6% and a 53.2% success rate. Brill covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Centessa Pharmaceuticals, and Palvella Therapeutics. ;'>

Maze Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $63.50, which is a 144.2% upside from current levels. In a report issued on May 12, TD Cowen also maintained a Buy rating on the stock.

PACS Group Inc (PACS)

In a report released today, A.J. Rice from UBS maintained a Buy rating on PACS Group Inc, with a price target of $50.00. The company’s shares closed last Wednesday at $41.30, close to its 52-week high of $43.92.

According to TipRanks.com, Rice is a 5-star analyst with an average return of 8.0% and a 59.2% success rate. Rice covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Ardent Health Partners, Inc., and Cross Country Healthcare. ;'>

PACS Group Inc has an analyst consensus of Strong Buy, with a price target consensus of $48.80, a 19.6% upside from current levels. In a report issued on May 12, TipRanks – PerPlexity also upgraded the stock to Buy with a $36.00 price target.

Read More on SI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).